No Data
No Data
Travere Therapeutics, Inc. (NASDAQ:TVTX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Scotiabank Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Cuts Target Price to $30
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $47
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $47
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Cantor Fitzgerald Maintains Travere Therapeutic(TVTX.US) With Buy Rating